TRC253 Showing Effectiveness in Metastatic Castration-resistant Prostate Cancer Patients

TRC253 Showing Effectiveness in Metastatic Castration-resistant Prostate Cancer Patients
The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the first part of a Phase 1/2a clinical trial. The second part of the study (NCT02987829) is currently enrolling at several U.S. locations and is using the recommended 280 mg dose. (More information on study sites and contacts is available here.) The study, “An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer,” was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the 2019 ASCO Annual Meeting Proceedings. TRC253 is a small molecule developed by Tracon Pharmaceuticals that selectively blocks the androgen receptor (AR), whose activation is key for the growth of prostate cancer at all stages. Although prior therapies targeting the AR have prolonged the time to disease
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *